About Rob

Rob is a managing director with the Health Care Advisory Board research program and leads strategic research in support of hospital and health system executives.

Rob dedicates a substantial portion of his time to working directly with members onsite, educating leadership teams and boards about market developments and the key implications for provider strategy. His principal areas of expertise include major industry trends, hospital-physician integration strategy, and accountable care strategy. One of the firm’s leading experts on bundled payment and accountable care organization programs, Rob has been cited by a range of national media outlets, including The Wall Street Journal, Modern Healthcare, Kaiser Health News, and Becker’s Hospital Review.

Rob's interest in improving health care extends beyond his work at the Advisory Board. From 2014 to 2020, he served on the Board of Directors of Community of Hope, a federally qualified health center working to improve health and end family homelessness to make Washington, D.C. more equitable.

Prior to joining the Advisory Board in 2006, Rob served in the Office of the Health Insurance Commissioner in the state of Rhode Island and the U.S. Food and Drug Administration’s Center for Devices and Radiological Health.

Rob graduated from Brown University with a Bachelor of Arts degree in Public Policy and American Institutions.

Rob specializes specifically in major industry trends, health policy, bundled payments, accountable care organizations, hospital-physician partnership, and strategy.

Follow Rob on Twitter @roblazerow.

Areas of expertise

Strategy, Health Policy, Market Trends, Bundled Payments, Accountable Care, Physician Strategy, Physician Issues,

Rob Lazerow

Rob Lazerow

Managing Director

Ask an Expert
Get in touch with Rob

Rob's Upcoming Events

Apr 15 2019

2018-19 Health Care Advisory Board National Meeting

In this series, we explored the most important forces reshaping the health care industry and provide guidance on how to stay a step ahead, including practical steps to rein in expenses (especially pharmaceutical spending) and how to secure future growth by winning on three fronts. More Register